DOCSLIB.ORG

Booklet 2020 - Public Version

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Booklet 2020 - Public Version booklet 2020 - public version Contact Information: Tabea Wiedmer, RESOLUTE Scientific Project Manager [email protected] c/o CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Lazarettgasse 14, AKH BT 25.3 1090 Vienna, Austria Álvaro Inglés-Prieto, RESOLUTE Communications and Business Development Manager [email protected] Giulio Superti-Furga, CeMM Academic Project Coordinator [email protected] Claire Steppan, Pfizer Ltd. EFPIA Project Leader [email protected] The RESOLUTE (https://re-solute.eu/) project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777372. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. RESOLUTE Research empowerment on solute carriers List of participants Participant No. Participant organization name Country CeMM Research Center for Molecular Medicine of the 1 Austria Austrian Academy of Sciences (CeMM) 2 University of Oxford (UOX) UK 3 University of Liverpool (ULIV) UK 4 Axxam SpA (AXXAM) Italy 5 Universiteit Leiden (ULEI) Netherlands 6 Max-Planck Institut für Medizinische Forschung (MPIMR) Germany 7 Universität Wien (UNIVIE) Austria 8 Pfizer Ltd. (Pfizer) UK 9 Novartis Pharma AG (Novartis) Switzerland 10 Boehringer Ingelheim Pharma GmbH (Boehringer) Germany 11 Vifor (International) AG (Vifor) Switzerland 12 Sanofi Recherche et Développement (Sanofi) France 13 Bayer AG (Bayer) Germany Table of Contents 1. EXCELLENCE .......................................................................................................................................... 2 1.1 OBJECTIVES ...................................................................................................................................... 2 1.2 RELATION TO THE CALL TOPIC TEXT ........................................................................................................ 3 1.3 CONCEPT AND APPROACH .................................................................................................................... 5 1.4 AMBITION ........................................................................................................................................ 7 2. IMPACT ................................................................................................................................................ 9 2.1 EXPECTED IMPACTS ............................................................................................................................ 9 2.2 MEASURES TO MAXIMISE IMPACT ........................................................................................................ 11 3. IMPLEMENTATION ............................................................................................................................. 16 3.1 PROJECT PLAN — WORK PACKAGES, DELIVERABLES AND MILESTONES ......................................................... 16 3.2 MANAGEMENT STRUCTURE AND PROCEDURES ....................................................................................... 56 3.3 CONSORTIUM AS A WHOLE ................................................................................................................ 64 3.4 RESOURCES COMMITTED ................................................................................................................... 68 4. MEMBERS OF THE CONSORTIUM ....................................................................................................... 69 4.1 PARTICIPANTS (APPLICANTS) .............................................................................................................. 69 4.2 THIRD PARTIES INVOLVED IN THE PROJECT (INCLUDING USE OF THIRD PARTY RESOURCES) ................................. 92 5. ETHICS ................................................................................................................................................ 93 6. REFERENCES ....................................................................................................................................... 95 7. ABBREVIATIONS ................................................................................................................................. 97 Page | 1 RESOLUTE Research empowerment on solute carriers List of participants Participant No. Participant organization name Country CeMM Research Center for Molecular Medicine of the 1 Austria Austrian Academy of Sciences (CeMM) 2 University of Oxford (UOX) UK 3 University of Liverpool (ULIV) UK 4 Axxam SpA (AXXAM) Italy 5 Universiteit Leiden (ULEI) Netherlands 6 Max-Planck Institut für Medizinische Forschung (MPIMR) Germany 7 Universität Wien (UNIVIE) Austria 8 Pfizer Ltd. (Pfizer) UK 9 Novartis Pharma AG (Novartis) Switzerland 10 Boehringer Ingelheim Pharma GmbH (Boehringer) Germany 11 Vifor (International) AG (Vifor) Switzerland 12 Sanofi Recherche et Développement (Sanofi) France 13 Bayer AG (Bayer) Germany Table of Contents 1. EXCELLENCE .......................................................................................................................................... 2 1.1 OBJECTIVES ...................................................................................................................................... 2 1.2 RELATION TO THE CALL TOPIC TEXT ........................................................................................................ 3 1.3 CONCEPT AND APPROACH .................................................................................................................... 5 1.4 AMBITION ........................................................................................................................................ 7 2. IMPACT ................................................................................................................................................ 9 2.1 EXPECTED IMPACTS ............................................................................................................................ 9 2.2 MEASURES TO MAXIMISE IMPACT ........................................................................................................ 11 3. IMPLEMENTATION ............................................................................................................................. 16 3.1 PROJECT PLAN — WORK PACKAGES, DELIVERABLES AND MILESTONES ......................................................... 16 3.2 MANAGEMENT STRUCTURE AND PROCEDURES ....................................................................................... 56 3.3 CONSORTIUM AS A WHOLE ................................................................................................................ 64 3.4 RESOURCES COMMITTED ................................................................................................................... 68 4. MEMBERS OF THE CONSORTIUM ....................................................................................................... 69 4.1 PARTICIPANTS (APPLICANTS) .............................................................................................................. 69 4.2 THIRD PARTIES INVOLVED IN THE PROJECT (INCLUDING USE OF THIRD PARTY RESOURCES) ................................. 92 5. ETHICS ................................................................................................................................................ 93 6. REFERENCES ....................................................................................................................................... 95 7. ABBREVIATIONS ................................................................................................................................. 97 www.imi.europa.eu 1. EXCELLENCE 1.1 Objectives RESOLUTE is resolved to create a decisive advancement in the overall tractability of the Solute Carrier class of protein transporters (SLCs) by providing practical and conceptual advances, and making its research output available openly and pre-competitively to the scientific community. We argue that the ~400 members of this class represent a largely untapped source of new potential drug targets and thus merit the efficiency of scale that can be achieved only through systematic and coordinated efforts [1]. Indeed, because SLC family members operate in an integrated manner over a common metabolic space, we argue that this superfamily can best be approached by a holistic game plan that takes functional networks into consideration. The spectrum of similarities among SLCs that will be identified in the deorphanisation process will offer unparalleled opportunities to infer kinship in mechanism or ligand specificity. RESOLUTE has one over-arching vision: To trigger an escalation in the appreciation and intensity of SLC research worldwide and establish SLCs as a tractable target class (Fig. 1). RESOLUTE has two non-renounceable high-level objectives: 1. To create a comprehensive set of long-lasting, intensely characterized tools enabling SLC research and packages of reliable knowledge for the majority of SLCs. 2. To develop robust functional assays for at least 50 of the 72 prioritized SLCs. RESOLUTE has 16 specific objectives: 1. To create vectors for eukaryotic expression of all human SLC genes. 2. To engineer loss-of-function SLC cell lines as physiologically relevant as possible. 3. To create tagged over-expressed versions of all human SLC cDNAs. 4. To generate and validate renewable and recombinant antibodies and high affinity engineered binding scaffolds against
Load more

Recommended publications
  • Bioinformatics Companies
    Bioinformatics companies Clondiag Chip Technologies --- ( http://www.clondiag.com/ ) Develops software for the analysis and management of microarray data. Tripos, Inc. --- ( http://www.tripos.com/ ) Provider of discovery research software & services to pharmaceutical, biotechnology, & other life sciences companies worldwide. Applied Biosystems --- ( http://www.appliedbiosystems.com ) Offers instrument-based software for the discovery, development, and manufacturing of drugs. ALCARA BioSciences --- ( http://www.aclara.com/ ) Microfluidics arrays ("lab-on-a-chip") for high-throughput pharmaceutical drug screening, multiplexed gene expression analysis, and multiplexed SNP genotyping. BioDiscovery, Inc. --- ( http://www.biodiscovery.com ) Offers microarray bioinformatics software and services. Structural Bioinformatics, Inc. --- ( http://www.strubix.com/ ) Expediting lead discovery by providing structural data and analysis for drug targets. GenOdyssee SA --- ( http://www.genodyssee.com/ ) Provides to the pharmaceutical, diagnostic and biotech industry full range of post-genomic services : HT SNP discovery and genotyping, and functional proteomics. AlgoNomics --- ( http://www.algonomics.com ) Provides online, as well as on-site, tools for protein sequence analysis and structure prediction. Focused on the relationship between the amino acid sequence of proteins and their function. VizXlabs --- ( http://vizxlabs.com/ ) Develops software systems for the acquisition, management and analysis of molecular biology data and information. Rosetta Inpharmatics
    [Show full text]
  • Genedata Selector for NGS-Based Biosafety Testing
    Genedata Selector for NGS-Based Biosafety Testing INDUSTRY Next-generation sequencing (NGS) is becoming increasingly important for the rapid identifi- Biopharmaceutical R&D cation of adventitious agents (e.g., viruses and mycoplasma) introduced during biopharma- ceutical development and manufacturing. Key advantages of NGS compared to traditional APPLICATION Adventitious Agent assays are faster, more accurate, and more sensitive results (Figure ). The biopharmaceuti- Detection cal industry recognizes that it is crucial to screen for adventitious agents regularly, as failure Cell-line Stability to detect them early can have devastating financial consequences. Particularly for evolving cell and gene therapy approaches with only short timelines between manufacturing and KEY CHALLENGE delivery to patients, efficient and rapid biosafety testing with NGS is crucial. NGS data analysis SUMMARY Assessing the presence of adventitious agents using NGS provides scientists with an unbi- Genedata Selector ased approach, which is suitable for testing starting materials, unprocessed bulk harvest, as automates NGS-based well as the final product. NGS-based biosafety assessment requires sequence data of the biosafety data processing, samples to be assessed, genomic data of the production host, and a reference sequence analysis and report database of adventitious agents (e.g., rVDB, etc.). These data need to be analyzed efficiently generation. using sophisticated algorithms to make data-driven decisions on biosafety (Figure ). GENEDATA SOLUTION Genedata Selector® is an end-to-end software solution that enables biopharmaceutical or- ganizations to make data-driven GO/NO-GO decisions regarding product safety, quality, and integrity with significant time savings. By providing out-of-the-box pipelines for automated NGS data analysis, Genedata Selector empowers scientists to implement biosafety testing in house without the need for extensive bioinformatics training.
    [Show full text]
  • 6Th Symposium on the Practical Applications of Mass Spectrometry
    13th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (Mass Spec 2016) Symposium Co-Chairs: Eef Dirksen, Synthon Biopharmaceuticals B.V. Christopher Yu, Genentech, a Member of the Roche Group September 27-30, 2016 The Westin San Diego Hotel San Diego, CA USA Organized by 1 Table of Contents Welcome Letter ................................................................................................. 3 Student Travel Grants ....................................................................................... 4 Program, Exhibitor and Media Partners ........................................................... 5 Scientific Program Summary ............................................................................ 8 Plenary and Session Abstracts .......................................................................... 16 Round Robin Table Topics ............................................................................... 40 Technical Seminar Abstracts ............................................................................ 42 Poster Abstracts ................................................................................................ 48 2 Welcome to the 13th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry We are pleased to welcome you to the 13th Symposium on the Practical Application of Mass Spectrometry in the Biotechnology Industry. The focus of this Symposium is the application of mass spectrometry for product characterization, process
    [Show full text]
  • 6Th Symposium on the Practical Applications of Mass
    13th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (Mass Spec 2016) Symposium Co-Chairs: Eef Dirksen, Synthon Biopharmaceuticals B.V. Christopher Yu, Genentech, a Member of the Roche Group September 27-30, 2016 The Westin San Diego San Diego, CA USA Organized by 1 Table of Contents Student Travel Grants ....................................................................................... Program, Exhibitor and Media Partners ........................................................... Scientific Program Summary ............................................................................ Plenary and Session Abstracts .......................................................................... Roundtable Topics ............................................................................................ Technical Seminar Abstracts ............................................................................ Poster Abstracts ................................................................................................ 2 Welcome to the 13th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry We are pleased to welcome you to the 13th Symposium on the Practical Application of Mass Spectrometry in the Biotechnology Industry. The focus of this Symposium is the application of mass spectrometry for product characterization, process monitoring, formulation development and release testing in the pharmaceutical industry. Since mass spectrometry is a critical technology
    [Show full text]
  • Genedata Selector for NGS-Based Biosafety Testing
    Genedata Selector for NGS-Based Biosafety Testing INDUSTRY Next-generation sequencing (NGS) is becoming increasingly important for the rapid identifi- Biopharmaceutical R&D cation of contaminants introduced during biopharmaceutical development and manufactur- ing. Key advantages of NGS are faster, more accurate, and more sensitive results compared APPLICATION Adventitious Agent to traditional methods (Figure ). Manufacturing groups recognize that it is crucial to screen Detection for adventitious agents (e.g., viruses) regularly as failure to detect them early can have dev- Cell-line Stability astating financial consequences. Especially for evolving cell and gene therapy approaches where there are only short time frames between manufacturing and delivery to patients, KEY CHALLENGE efficient and rapid biosafety testing with NGS is crucial. NGS data analysis SUMMARY Assessing the presence of adventitious agents using NGS provides scientists with an unbi- Genedata Selector ased approach, as sequencing detects all organisms. This approach is suitable for testing automates NGS-based starting materials, unprocessed bulk harvest, and the final product. Prerequisites of an NGS- biosafety data processing, based biosafety assessment include sequence data, reference genomes of the production analysis and report host, and a reference database of adventitious agents (e.g., rVDB, etc.). These need to be generation. analyzed efficiently using sophisticated algorithms to gain actionable scientific insights. GENEDATA SOLUTION Genedata Selector® is an end-to-end software solution that enables biopharmaceutical R&D organizations to make data-driven GO/NO-GO decisions regarding product safety, quality, and integrity with significant time savings. By providing out-of-the-box bioinformatics pipelines for automated NGS data processing and analysis, Genedata Selector empowers scientists to implement biosafety testing in house without the need for extensive bioinfor- matics training.
    [Show full text]